Hedy Kindler, MD
Enriched profileAssociate Dean for Clinical Science Research, Human Subjects, and Professor of Medicine (Section of Hematology/Oncology), University of Chicago Pritzker School of Medicine · University of Chicago
Hedy Kindler is Associate Dean for Clinical Science Research, Human Subjects, and Professor of Medicine (Section of Hematology/Oncology), University of Chicago Pritzker School of Medicine at University of Chicago. OpenAlex indexes 662 publications with 39,455 citations (h-index 91); ClinicalTrials.gov lists 35 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Hedy Kindler is Associate Dean for Clinical Science Research, Human Subjects, and Professor of Medicine (Section of Hematology/Oncology), University of Chicago Pritzker School of Medicine. The public record shows 662 publications with 39,455 citations (h-index 91), centered on Occupational and environmental lung diseases, Pancreatic and Hepatic Oncology Research, Pleural and Pulmonary Diseases. It also documents an investigator role on 35 registered clinical trials, industry payments reported by 7 companies, 6 NIH-funded awards (2000–2026).
- Most recent indexed publication: 2025 · JCO oncology practice
- Top research focus: Occupational and environmental lung diseases
- 35 registered trials on ClinicalTrials.gov
- Open Payments reporting from 7 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 13 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 319.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Expert Panel Co-Chair
ASCO Guidelines Committee update on treatment of malignant pleural mesothelioma
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.uchicago.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopubs.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 35 registered studies on ClinicalTrials.gov. The most recent:
- Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Sponsor: Tango Therapeutics, Inc.
- Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
Sponsor: Alliance for Clinical Trials in Oncology
- Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 27 Aug 2026
7 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20241 payment
- Amgen Inc.Program year20242 payments
- SANOFI US SERVICES INC.Program year20231 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
35.1%Factor Xa inhibitor35.1%Eliquis100%Part D<11 patientsCancer & immunology
25.8%Kinase inhibitor25.8%Imatinib Mesylate100%Part D<11 patientsSensory organs
19.6%Corticosteroid19.6%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
6 NIH research awards on record, funded 2000–2026 per NIH RePORTER. The latest:
Congress activity
Updated 27 Aug 2026
163 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- LBA104 Primary results of DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma: A phase III randomised trial
ESMO Congress
ESMO2025Co-authorLate-breaking - Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients (pts) with advanced solid tumors or hematologic malignancies.
ASCO Annual Meeting
ASCO2024Co-author - Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations
AACR Annual Meeting
AACR2023Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights.
JCO oncology practice
Article2025 - Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
American journal of clinical pathology
Review2023 - Management of Patients With Pancreatic Cancer Using the "Right Track" Model.
The oncologist
Review2023
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic CancerArticle2,231 citations2019
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
State University of New York at Buffalo (SUNY Buffalo)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.uchicago.edu ↗ - Internal Medicine residency
UCLA and Montefiore Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.uchicago.edu ↗ - Fellowship in Hematology/Oncology
Memorial Sloan Kettering Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.uchicago.edu ↗ - Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.uchicago.edu ↗
- Director
Multidisciplinary Mesothelioma Program, University of Chicago Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗ - Medical Director
Gastrointestinal Oncology, University of Chicago Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mesothelioma-lung-cancer.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.uchicago.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗
Secondary affiliations
appointments beyond the home institution- Executive Committee member
Alliance for Clinical Trials in Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.uchicago.edu ↗ - Member
Mesothelioma Task Force, International Association for the Study of Lung Cancer (IASLC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.uchicago.edu ↗ - Member
Science Advisory Board, Mesothelioma Applied Research Foundation / Mesothelioma Foundation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uchicagomedicine.org ↗
Media & interviews
press, podcasts and appearances- ASCO Guidelines podcast: "Treatment of Pleural Mesothelioma Update" (ASCO Publications, Jan 2025)
discussing ASCO guideline she co-led
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopubs.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →curemeso.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podomatic.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Everett Vokes, MD
University of Chicago
Ralph Weichselbaum, MD
University of Chicago
Mary Rinella, MD
University of Chicago
Samuel Refetoff, MD
University of Chicago